Patents by Inventor Peter Valent
Peter Valent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10383955Abstract: The present invention relates to a human mast cell line corresponding to deposit number CNCM I-4551 and also to the lines derived therefrom, in particular the derived lines corresponding respectively to deposit numbers CNCM I-4552 and CNCM I-4553, and to the uses thereof, in particular for screening for compounds of therapeutic interest.Type: GrantFiled: November 2, 2012Date of Patent: August 20, 2019Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE DE CACHAN, MEDIZINISCHE UNIVERSITAT WIENInventors: Michel Arock, Peter Valent, Rosine Saleh, Ghaith Wedeh, Christian Auclair
-
Patent number: 9963489Abstract: An immobilized polypeptide including a polypeptide bound to a surface of a polypeptide array or a chip, wherein the polypeptide has the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:1 lacking the N-terminal methionine, SEQ ID NO:3 lacking the N-terminal methionine, or a combination thereof.Type: GrantFiled: December 16, 2016Date of Patent: May 8, 2018Assignee: BIOMAY AGInventors: Rudolf Valenta, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
-
Publication number: 20180022808Abstract: The present invention relates to an antibody construct comprising at least one antigen binding site specific for ICAM1 and at least one antigen binding site specific for at least one allergen.Type: ApplicationFiled: February 10, 2016Publication date: January 25, 2018Inventors: Christoph Madritsch, Sabine Flicker, Rudolf Valenta, Elisabeth Gader-Maier, Julia Eckl-Dorna, Verena Niederberger, Katharina Blatt, Peter Valent, Isabella Ellinger
-
Publication number: 20170218034Abstract: An immobilized polypeptide including a polypeptide bound to a surface of a polypeptide array or a chip, wherein the polypeptide has the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:1 lacking the N-terminal methionine, SEQ ID NO:3 lacking the N-terminal methionine, or a combination thereof.Type: ApplicationFiled: December 16, 2016Publication date: August 3, 2017Applicant: Biomay AGInventors: Rudolf VALENTA, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
-
Patent number: 9296828Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.Type: GrantFiled: June 11, 2007Date of Patent: March 29, 2016Assignee: BIOMAY AGInventors: Rudolf Valenta, Margarete Focke-Tejkl, Birgit Linhart, Susanne Vrtala, Peter Valent, Renate Reininger, Susanne Spitzauer, Ines Swoboda, Marianne Van Hage, Hans Grönlund, Johanna Tinhofer, Kerstin Westritschnig, Theresia Popow-Kraupp
-
Patent number: 9103835Abstract: The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.Type: GrantFiled: September 9, 2010Date of Patent: August 11, 2015Assignee: BIOMAY AGInventors: Rudolf Valenta, Birgit Linhart, Margarete Focke-Tejkl, Angela Neubauer, Peter Valent, Katharina Blatt
-
Publication number: 20150104458Abstract: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.Type: ApplicationFiled: August 26, 2014Publication date: April 16, 2015Applicant: Biomay AGInventors: Rudolf VALENTA, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
-
Publication number: 20140298497Abstract: The present invention relates to a human mast cell line corresponding to deposit number CNCM I-4551 and also to the lines derived therefrom, in particular the derived lines corresponding respectively to deposit numbers CNCM I-4552 and CNCM I-4553, and to the uses thereof, in particular for screening for compounds of therapeutic interest.Type: ApplicationFiled: November 2, 2012Publication date: October 2, 2014Inventors: Michel Arock, Peter Valent, Rosine Saleh, Ghaith Wedeh, Christian Auclair
-
Publication number: 20140121356Abstract: The present invention relates to non-naturally occurring polypeptides derived from fish allergens such as parvalbumin Cyp c 1.01 from carp. The polypeptides display reduced allergenic activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.Type: ApplicationFiled: December 20, 2013Publication date: May 1, 2014Applicant: BIOMAY PRODUKTIONS- UND HANDELS-AKTIENGESELLSCHAFTInventors: Rudolf VALENTA, Peter Valent, Susanne Spitzauer, Ines Swoboda
-
Patent number: 8709435Abstract: Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.Type: GrantFiled: July 8, 2011Date of Patent: April 29, 2014Assignee: Biomay AGInventors: Raffaela Campana, Rudolf Valenta, Susanne Vrtala, Ines Swoboda, Margarete Focke-Tejkl, Anna Gieras, Susanne Spitzauer, Peter Valent, Katharina Blatt, Birgit Linhart, Dietrich Kraft
-
Patent number: 8440200Abstract: Methods for desensitization of a mammal suffering from IgE mediated allergy comprise the steps of: administering to said mammal a therapeutically effective amount of an immunogenic and hypoallergenic composition which comprises (i) a Phl p 6 molecule having an N-terminal truncation which makes the molecule at least lack IgE binding capacity, and/or (ii) a Phl p 6 molecule having a C-terminal truncation which makes the molecule at least lack IgE binding capacity, wherein the molecules of (i) and (ii), if employed in combination, together span the complete sequence of Phl p 6, and a pharmaceutically acceptable carrier.Type: GrantFiled: November 1, 2007Date of Patent: May 14, 2013Assignee: Phadia ABInventors: Rudolf Valenta, Susanne Vrtala, Sabine Stumvoll, Hans Grönlund, Monika Grote, Luca Vangelista, Annalisa Pastore, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft
-
Publication number: 20120207788Abstract: The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.Type: ApplicationFiled: September 9, 2010Publication date: August 16, 2012Applicant: BIOMAY AGInventors: Rudolf Valenta, Birgit Linhart, Margarete Focke-Tejkl, Angela Neubauer, Peter Valent, Katharina Blatt
-
Publication number: 20120009210Abstract: Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.Type: ApplicationFiled: July 8, 2011Publication date: January 12, 2012Applicant: BIOMAY AGInventors: Raffaela Campana, Rudolf Valenta, Susanne Vrtala, Ines Swoboda, Anna Gieras, Susanne Spitzauer, Peter Valent, Katharina Blatt, Margarete Focke-Tejkl, Birgit Linhart, Dietrich Kraft
-
Patent number: 8076321Abstract: The present invention relates to the use of the combination of tyrosine phosphate inhibitors AMN107 and PKC412 for the preparation of a drug for the treatment of a mast cell-related proliferative disease. The present invention is also drawn to a combination treatment of a tyrosine phosphate inhibitor and a TK-inhibitor that is effective against a mast cell-related proliferative disease, including especially systemic mastocytosis (SM) including aggressive SM (ASM) and mast cell leukemia (MCL).Type: GrantFiled: July 19, 2006Date of Patent: December 13, 2011Inventor: Peter Valent
-
Publication number: 20100216717Abstract: The present invention relates to non-naturally occurring polypeptides derived from fish allergens such as parvalbumin Cyp c 1.01 from carp. The polypeptides display reduced allergenic activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.Type: ApplicationFiled: March 10, 2010Publication date: August 26, 2010Inventors: Rudolf Valenta, Peter Valent, Susanne Spitzauer, Ines Swoboda
-
Publication number: 20100184820Abstract: The present invention relates to a method of treating myelodysplastic syndromes, lymphomas and leukemias, and also solid tumors with a pharmaceutical combination of a FLT-3 kinase inhibitor and an antisense oligonucleotide or a mcl-1-specific RNAi construct. It also relates to the use of a pharmaceutical combination of a histone deacetylase inhibitor and a FLT-3 kinase inhibitor for the treatment of the diseases or malignancies mentioned above and the use of such a pharmaceutical composition for the manufacture of a medicament for the treatment of these diseases or malignancies.Type: ApplicationFiled: June 22, 2007Publication date: July 22, 2010Inventor: Peter Valent
-
Patent number: 7696314Abstract: The present invention relates to non-naturally occurring polypeptides derived from fish allergens such as parvalbumin Cyp c 1.01 from carp. The polypeptides display reduced allergenic activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.Type: GrantFiled: August 24, 2004Date of Patent: April 13, 2010Assignee: Biomay Produktions- und HandelsaktiengesellschaftInventors: Rudolf Valenta, Peter Valent, Susanne Spitzauer, Ines Swoboda
-
Publication number: 20090324501Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.Type: ApplicationFiled: June 11, 2007Publication date: December 31, 2009Applicant: Biomay AGInventors: Rudolf Valenta, Margarete Focke-Tejkl, Birgit Linhart, Susanne Vrtala, Peter Valent, Renat Reininger, Susanne Spitzauer, Ines Swoboda, Marianne Van Hage, Hans Grönlund, Johanna Tinhofer, Kerstin Westritschnig, Theresia Popow-Kraupp
-
Publication number: 20090221550Abstract: The present invention relates to the use of the combination of tyrosine phosphate inhibitors AMN107 and PKC412 for the preparation of a drug for the treatment of a mast cell-related proliferative disease. The present invention is also drawn to a combination treatment of a tyrosine phosphate inhibitor and a TK-inhibitor that is effective against a mast cell-related proliferative disease, including especially systemic mastocytosis (SM) including aggressive SM (ASM) and mast cell leukemia (MCL).Type: ApplicationFiled: July 19, 2006Publication date: September 3, 2009Inventor: Peter Valent
-
Patent number: RE42324Abstract: The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics: a) inhibits the IgE-Fc?RI interaction; b) binds to free and cell-bound IgE; and c) is non-anaphylactic.Type: GrantFiled: April 9, 2010Date of Patent: May 3, 2011Assignee: Phadia ABInventors: Sylvia Laffer, Erik Hogbom, Kenneth H. Roux, Jonas Adriansson, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Hans Grönlund, Rudolf Valenta